Head-to-head · Cost-Efficiency Index
NowPatient vs RegenCen
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NowPatient
Cost-first shoppers who want not clearly established for US GLP-1 shoppers based on available public pricing.
Visit NowPatientRegenCen
Shoppers near one of RegenCen's 23 Michigan/Florida/South Carolina clinics who prefer in-person care and don't need public pricing up front.
Visit RegenCenThe verdict
NowPatient and RegenCen tie on the Cost-Efficiency Index at 44/100, so neither wins outright on the numbers. For most shoppers we'd start with NowPatient (ranked #481, a hair above #484) — Cost-first shoppers who want not clearly established for US GLP-1 shoppers based on available public pricing. But RegenCen is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NowPatient.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NowPatient | RegenCen |
|---|---|---|
| Cost-Efficiency Index | 44/100 | 44/100 |
| Semaglutide / mo | Not disclosed | Not disclosed |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | — | — |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | 2 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #481 | #484 |
NowPatient
44/100Where the value is
- Established multi-country digital health platform with ISO/HIPAA/GDPR compliance claims
- Named medical director and superintendent pharmacist on the site
- Broader platform includes prescription-savings and monitoring tools beyond just GLP-1s
The tradeoffs
- No US GLP-1 pricing could be located on the site
- Named clinical leadership titles (Superintendent Pharmacist, GPhC) appear to be UK-specific, unclear US applicability
RegenCen
44/100Where the value is
- 23 real in-person clinic locations across three states (MI, FL, SC), unusually large physical footprint for this category
- Named, credentialed clinical leadership: Dr. Gustav Lo, CMO/Founder with 30+ years of experience, and co-founder Courtney Lo, PA
- Offers both semaglutide and tirzepatide under one regenerative-medicine practice
The tradeoffs
- No pricing of any kind — not even a 'starting at' figure — is published anywhere on the site; a phone call or booked consultation is required just to learn the cost
- Coverage is effectively limited to Michigan, Florida, and one South Carolina location plus telehealth in only two of those states
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.